Please login to the form below

Not currently logged in
Email:
Password:

UK's ABPI rejects GMC off-label suggestions

The ABPI has responded to the GMC's consultation on prescribing off-label drugs

Prescribing off-label drugs when a licensed alternative exists increases risks to patients and threatens the development of new medicines, the Association of the British Pharmaceutical Industry (ABPI) has said in response to the General Medical Council's (GMC) consultation on the matter.

The GMC is proposing to allow doctors to prescribe drugs off-label when there is a licensed alternative, as this "does not interfere with their [doctors'] ethical considerations," in an attempt to make off-label use clearer to its members.

However, the ABPI said that even if doctors believe it is the right thing to do, off-label prescribing will continue to put patients at risk, because of a lack of safety data for non-approved uses for drugs.

It said: "ABPI recommends that the GMC maintains unchanged its existing guidance (2008) on the use of off-label and unlicensed medicines, which emphasises that while doctors should make 'good use of the resources available' this does not extend to prescribing a medicine outside the terms of its licence, unless the doctor is satisfied that it would better serve the patient's needs than a licensed alternative.

"The existing guidance does not imply that cost can be an acceptable consideration in choosing an unlicensed medicine when there is a licensed alternative that meets the same clinical need."

6th June 2011

Share

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Collected Group

Collected Group is a forward thinking healthcare communication company that supports biopharma and diagnostic companies to engage in more lasting...

Latest intelligence

Infographic: Therapy Watch Hyperlipidaemia
Our latest infographic offers an introduction to the real-world insights collected by our Hyperlipidaemia study....
Article: The rise of the healthcare influencer
In our latest article for Pharmaphorum Deep Dive, we explore the opportunities and benefits for healthcare companies in the online influencer space....
Top-10 Reasons Why You Should be Adding Asynchronous Virtual Touchpoints Between Your Real-time Meetings
...